Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020)
Agios Pharmaceuticals' (AGIO) quarterly Liabilities from Discontinued Operations came in at 298814000.0 in Q1 2021, up 14.37% on a QoQ basis from 261269000.0 in Q4 2020.
Powered by 
Analysis
Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 298814000.0 in Q1 2021.
- Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 298814000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was 298814000.0 (changed N/A YoY) and the FY2020 annual result came in at 261269000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations advanced to 298814000.0 in Q1 2021, from 261269000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 298814000.0 in Q1 2021 to a low of 261269000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Agios Pharmaceuticals | 1.98 Bn | 1.98 Bn | 41.75 Mn |